Entrada Therapeutics slips on wider-than-expected Q3 loss

Entrada Therapeutics

07/11/2022 17:45

** Shares of Entrada Therapeutics Inc  TRDA.O  fall 8.6% to
~$20
    ** Co posted Q3 diluted loss of 80 cents/shr while analysts'
expected loss of 76 cents for the quarter - Refinitiv IBES 
    ** ANNX's Q3 R&D expenses were $19.0 mln vs $10.5 mln a year
earlier, primarily due to investment in preclinical studies to
support future clinical trials, enhanced facility and
equipment-related investments 
    ** Including session's fall, stock up 17.7% YTD 
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))